Overview

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Collaborator:

Novartis Pharmaceuticals

Treatments:

Ciprofloxacin